SciSparcNASDAQ: SPRC

TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the European Patent Office granted the Company's patent application titled “Compositions and Methods of Potentiating Antimicrobials”. This is in addition to the patent titled “Compositions and Methods of Potentiating Antimicrobials” previously granted by the United States Patent and Trademark Office. This patent grant bolsters the Company's intellectual property portfolio, extending the protection of its global patent holdings.

Cannabinoid biotech specialist SciSparc (NASDAQ: SPRC ) is enjoying a much-needed boost on Wednesday thanks to a key investment deal. This morning, management announced an equity purchase agreement with a private-equity fund, reflecting confidence in the otherwise embattled business.

Shares of drug discovery specialist SciSparc (NASDAQ: SPRC ) are popping sharply today on encouraging clinical study results. Specifically, the company's joint venture (JV) project MitoCareX Bio achieved positive results regarding small-molecule screening processes.

SciSparc Ltd.'s stock SPRC was up 74% on Friday, two days after the clinical-stage biopharmaceutical company said it agreed to merge with an unnamed company in Israel.

SciSparc (NASDAQ: SPRC ) stock is rising higher on Wednesday as investors react to the company signing a letter of intent for a merger. That merger would be with a leading vehicle importer company in Israel that goes unnamed in the SciSparc press release.

SciSparc (NASDAQ: SPRC ) stock is taking off on Wednesday after the company released results from a Phase IIa trial of SCI-110 as an Alzheimer's Disease agitation treatment. The clinical trial covered 18 patients with Alzheimer's who have been dealing with agitation symptoms.

SciSparc (NASDAQ: SPRC ) stock is taking off on Tuesday after the pharmaceutical company posted positive patent news. The big news here is the company's patent for ‘Combination of Opioids and N-Acylethanolamines for pain treatment” getting approval from IP Australia.